Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

医学 拓扑替康 卡铂 依托泊苷 打开标签 内科学 肿瘤科 肺癌 二线治疗 外科 临床试验 化疗 顺铂
作者
Nathalie Baize,I. Monnet,Laurent Greillier,Margaux Geier,H. Léna,Henri Janicot,A. Vergnenègre,Jacky Créquit,R. Lamy,J.B. Auliac,J. Letreut,H. Le Caer,Radj Gervais,Éric Dansin,Anne Madroszyk,P Renault,G. Le Garff,L. Falchero,H. Bérard,Roland Schött
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (9): 1224-1233 被引量:151
标识
DOI:10.1016/s1470-2045(20)30461-7
摘要

Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line treatment in patients with sensitive relapsed small-cell lung cancer.In this open-label, randomised, phase 3 trial done in 38 hospitals in France, we enrolled patients with histologically or cytologically confirmed advanced stage IV or locally relapsed small-cell lung cancer, who responded to first-line platinum plus etoposide treatment, but who had disease relapse or progression at least 90 days after completion of first-line treatment. Eligible patients were aged 18 years or older and had an Eastern Cooperative Oncology Group performance status 0-2. Enrolled patients were randomly assigned (1:1) to receive combination carboplatin plus etoposide (six cycles of intravenous carboplatin [area under the curve 5 mg/mL per min] on day 1 plus intravenous etoposide [100 mg/m2 from day 1 to day 3]) or oral topotecan (2·3 mg/m2 from day 1 to day 5, for six cycles). Randomisation was done using the minimisation method with biased-coin balancing for ECOG performance status, response to the first-line chemotherapy, and treatment centre. The primary endpoint was progression-free survival, which was centrally reviewed and analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02738346.Between July 18, 2013, and July 2, 2018, we enrolled and randomly assigned 164 patients (82 in each study group). One patient from each group withdrew consent, therefore 162 patients (81 in each group) were included in the intention-to-treat population. With a median follow-up of 22·7 months (IQR 20·0-37·3), median progression-free survival was significantly longer in the combination chemotherapy group than in the topotecan group (4·7 months, 90% CI 3·9-5·5 vs 2·7 months, 2·3-3·2; stratified hazard ratio 0·57, 90% CI 0·41-0·73; p=0·0041). The most frequent grade 3-4 adverse events were neutropenia (18 [22%] of 81 patients in the topotecan group vs 11 [14%] of 81 patients in the combination chemotherapy group), thrombocytopenia (29 [36%] vs 25 [31%]), anaemia (17 [21%] vs 20 [25%]), febrile neutropenia (nine [11%] vs five [6%]), and asthenia (eight [10%] vs seven [9%]). Two treatment-related deaths occurred in the topotecan group (both were febrile neutropenia with sepsis) and no treatment-related deaths occurred in the combination group.Our results suggest that carboplatin plus etoposide rechallenge can be considered as a reasonable second-line chemotherapy option for patients with sensitive relapsed small-cell lung cancer.Amgen and the French Lung Cancer Group (Groupe Français de Pneumo-Cancérologie).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被AndrEw采纳,获得10
1秒前
phhhhh发布了新的文献求助10
1秒前
迷茫中完成签到 ,获得积分10
1秒前
ypres发布了新的文献求助10
1秒前
wu完成签到,获得积分10
1秒前
Jasper的应助被坚定如花采纳,获得10
3秒前
3秒前
桐桐的应助被CC采纳,获得20
3秒前
小马甲的应助被jjk采纳,获得10
3秒前
如意行天完成签到 ,获得积分10
5秒前
LZH完成签到,获得积分10
5秒前
6秒前
kali发布了新的文献求助10
6秒前
wuhuiwen发布了新的文献求助10
7秒前
年轻的鹤完成签到,获得积分10
7秒前
7秒前
seashell发布了新的文献求助30
8秒前
8秒前
9秒前
温暖的台灯完成签到,获得积分10
9秒前
momo完成签到,获得积分10
9秒前
标致青雪发布了新的文献求助10
10秒前
SciGPT的应助被king采纳,获得10
10秒前
10秒前
10秒前
风之旅完成签到,获得积分10
11秒前
11秒前
菘蓝发布了新的文献求助10
11秒前
cjt完成签到 ,获得积分10
11秒前
12秒前
yjy完成签到 ,获得积分10
12秒前
王乐乐发布了新的文献求助10
13秒前
亦大艸凡完成签到,获得积分10
13秒前
14秒前
木维维发布了新的文献求助10
14秒前
赫江涛发布了新的文献求助10
14秒前
爆米花的应助被huigangwang采纳,获得10
14秒前
14秒前
如鱼得水完成签到,获得积分10
15秒前
坚定如花发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192020
求助须知:如何正确求助?哪些是违规求助? 9578648
关于积分的说明 21861105
捐赠科研通 7791458
什么是DOI,文献DOI怎么找? 3436765
关于科研通互助平台的介绍 2560502
邀请新用户注册赠送积分活动 2483544